Orion Biotech Opportunities Corp. Class A Ordinary Share
ORIA
ORIA was delisted on the 28th of April, 2023.
52 hedge funds and large institutions have $151M invested in Orion Biotech Opportunities Corp. Class A Ordinary Share in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 11 increasing their positions, 7 reducing their positions, and 5 closing their positions.
57% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 7
6% more capital invested
Capital invested by funds: $143M → $151M (+$8.25M)
0% more funds holding
Funds holding: 52 → 52 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCL
Glazer Capital LLC
New York
|
+$3.81M |
| 2 |
Jane Street
New York
|
+$3.69M |
| 3 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
+$1.52M |
| 4 |
FTCM
First Trust Capital Management
Chicago,
Illinois
|
+$901K |
| 5 |
Millennium Management
New York
|
+$675K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HighTower Advisors
Chicago,
Illinois
|
-$3.86M |
| 2 |
CCM
Context Capital Management
Lajolla,
California
|
-$1.04M |
| 3 |
CF
Cantor Fitzgerald
New York
|
-$999K |
| 4 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$738K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$329K |
ORIA Hedge Fund Activity: Q4 2022 in Review
52 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Orion Biotech Opportunities Corp. Class A Ordinary Share (ORIA) for Q4 2022, worth a combined $151M — up 5.8% from $143M a quarter earlier.
Fund positioning in ORIA was balanced in Q4 2022: 5 funds opened new positions, 5 closed out, 11 added to existing stakes and 7 trimmed.
The largest buyer was Glazer Capital LLC, adding an estimated $3.81M. The largest seller was HighTower Advisors, cutting an estimated $3.86M.
- 52 institutional investors held Orion Biotech Opportunities Corp. Class A Ordinary Share (ORIA) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $151M of Orion Biotech Opportunities Corp. Class A Ordinary Share stock for Q4 2022, up 5.8% quarter-over-quarter.
- 5 funds opened new Orion Biotech Opportunities Corp. Class A Ordinary Share positions in Q4 2022 and 5 closed out, a net change of 0 holders.
- The largest Orion Biotech Opportunities Corp. Class A Ordinary Share buyer in Q4 2022 was Glazer Capital LLC, an estimated $3.81M added.
- The largest Orion Biotech Opportunities Corp. Class A Ordinary Share seller in Q4 2022 was HighTower Advisors, an estimated $3.86M sold.
Based on aggregated 13F filings for Q4 2022.